Status and phase
Conditions
Treatments
About
This is a single arm, open label, phase II study to evaluate the activity of avelumab (MSB0010718C) in patients with metastatic or locally advanced urothelial cancer considered unfit to cisplatin-based chemotherapy, to be conducted in conformance with Good Clinical Practices.
Cisplatin-unfit patients will be defined if at least one of these characteristics is present:
Full description
Each subject will participate in the trial from the time the subject signs the Informed Consent Form (ICF) through the final contact. After a screening phase of 28 days, each subject will receive the treatment. Treatment on trial will continue until disease progression is confirmed by the investigator/site radiologist, unacceptable adverse event(s), intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the subject, subject withdrawals consent, pregnancy of the subject, noncompliance with trial treatment or procedures requirements, or administrative reasons.
The study treatment may be continued after radiological progression of disease at physician discretion and if improvement of symptoms or not new symptoms were reported by the patient despite the radiological progression of disease.
Subjects who attain a complete response may consider stopping trial treatment if they meet criteria for holding therapy.
After the end of treatment given the potential risk for delayed immune-related toxicities, safety follow-up must be performed up to 90 days after the last dose of avelumab administration.
The extended safety follow-up beyond 30 days after last study drug administration may be performed either via a site visit or via a telephone call with subsequent site visit requested in case any concerns noted during the telephone call.
Subjects who discontinue for reasons other than disease progression will have post-treatment follow-up every 12 weeks for disease status until disease progression is confirmed by the investigator/site radiologist, initiating a non-study cancer treatment, withdrawing consent, or becoming lost to follow-up. All subjects will be followed by telephone for overall survival every 12 weeks until death, withdrawal of consent, or the end of the trial.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
• Be able to understand and be willing to sign a written informed consent for the trial. Informed consent obtained before any study-specific procedures.
Creatinine Clearance < 60 ml/min;
Grade 2 or worse peripheral neuropathy or hearing loss;
Previous treatment with cisplatin for adjuvant intent in six months before the progression of disease.
• Demonstrate adequate bone-marrow, liver, and renal function as assessed by the following laboratory requirements conducted within 7 days of starting to study treatment:
Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L, and hemoglobin ≥ 9 g/dL (may have been transfused);
Total bilirubin ≤1∙5 × the upper limit of normal (ULN); or Direct bilirubin < ULN for subjects with total bilirubin levels >1.5xULN;
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), levels ≤ 2.5 × ULN or AST and ALT levels ≤ 5 x ULN (for subjects with documented metastatic disease to the liver);
International normalized ratio (INR) and partial thromboplastin time (PTT) ≤1∙5 × ULN. Subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate if no prior evidence of an underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR and PTT are stable based on a pre-dose measurement as defined by the local standard of care;
Platelet count ≥100.000/mm3, hemoglobin >9 g/dl, absolute neutrophil count >1.500/mm3;
Alkaline phosphatase limit ≤2∙5 × ULN (≤5 × ULN for patients with liver metastases).
Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method);
Pregnancy test: negative serum or urine pregnancy test at screening for women of childbearing potential.
Exclusion criteria
• Has disease that is suitable for local therapy administered with curative intent.
Exceptions cervical cancer in situ or basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy. A history of prostate cancer that was identified incidentally following cystoprostatectomy for bladder cancer is acceptable, provided that the following criteria are met:
Stage T2N0M0 or lower;
Gleason score ≤ 6,
PSA undetectable.
Has major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Has active cardiac disease, defined as:
Has uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic pressure >90 mmHg despite optimal medical management)
Has arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), pulmonary embolism within the 4 months before start of study medication.
Persisting toxicity related to prior therapy (NCI CTCAE v. 5.0 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable
Active infection higher than National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 grade 2 requiring systemic therapy.
Known history of testing positive for HIV or known acquired immunodeficiency syndrome.
Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).
Has seizure disorder requiring medication.
Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines
Has known symptomatic metastatic central nervous system (CNS) and/or meningeal tumors. Subjects with previously treated brain metastases may partecipate provided they are stable (the patient is >2 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable - any neurologic symptoms have returned to baseline - with respect to the tumor at the time of study entry). Also, the patient must not be undergoing acute steroid therapy or tapering (chronic steroid therapy is acceptable provided that the dose is stable for 1 month before and after screening radiographic studies). This exception does not include carcinomatous meningitis, which is excluded regardless of clinical stability.
Has a history of organ allograft.
Has evidence or history of bleeding diathesis. Any hemorrhage or bleeding event of CTCAE grade 3 or higher within 4 weeks of start of study medication.
Has non-healing wound, ulcer, or bone fracture.
Has renal failure requiring hemodialysis or peritoneal dialysis.
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.
Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
Dehydration of NCI-CTCAE version 5.0 grade 1 or higher.Prior organ transplantation including allogenic stem-cell transplantation.
Non-healing wound, ulcer, or bone fracture.
Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Has a history of substance abuse or medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
Has illness or medical conditions that are unstable or could jeopardize the safety of the patient and his or her compliance in the study.
Has interstitial lung disease with ongoing signs and symptoms at the time of informed consent.
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.
Primary purpose
Allocation
Interventional model
Masking
67 participants in 1 patient group
Loading...
Central trial contact
Roberto Iacovelli; ARIES Service
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal